METTL3 and acute myeloid leukemia: Compound 6 was able to downregulate m6A levels of AML MOLM-13 cells (m6A IC50 = 7 μM) and osteosarcoma U2OS cells (m6A IC50 = 9 μM) by inhibiting METTL3, demonstrating its potential antitumor efficacy.